الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 2 |  |  |
| | | from | 2 | | |
Abstract
The present study aimed to investigate the antioxidant, antiinflammatory, anti-apoptotic, and hepatoprotective possibilities of Cinnamaldehyde and lycopene versus hepatic biochemical alterations induced by monosodium glutamate. Rats are classified into seven groups group I-(control), group II-(MSG 15 mg/kg bw), group III-( MSG 35 mg/kg bw), group IV (MSG 15 mg/kg.bw + Cinnamaldehyde), group V (MSG 35 mg/kg.bw + Cinnamaldehyde), group VI (MSG 15 mg/kg bw + lycopene), group VII- (MSG 35 mg/kg bw + lycopene). our results demonstrated that administration of both doses of MSG (15, 35 mg/kg bw/day) for 30 days induced obesity, dyslipidemia, hyperglycemia, increase insulin resistance, hepatic toxicity and steatohepatitis and hepatic histopathological detrition comparing to control group. On contrary supplementation of cinnamaldehyde and lycopene (10 mg/kg bw/day) preMSG administration for 10 days and co- administration with MSG for 30 days in rats showed anti-obesity, hypolipidemic, antioxidant hepatoprotective, antidiabetic and anti-apoptosis effects. Anti-obesity activity via significant reduction in body weight gain and liver somatic index. Hypolipidemic effects indicated by significant decrease in TAG, TC, LDL-c and increased HDL-c. Hepatoprotective effects via reduction in liver enzymes (ALT, AST) activities and increased TAC, SOD, GSH, GPx,
in line with decreased MDA. Anti-inflammatory response as referred by lowered serum TNF-ɑ and IL6. Hypoglycemic and antidiabetic effects via decreased HOMA-IR, HOMA-β. Antifibrosis and anti-apoptosis properties as indicated by reduced hepatic TGF-β1, caspase-3 expression and elevated BCL2 expression. These findings were confirmed with improvement of histoarchitecture of liver with better ameliorative effects for cinnamaldehyde comparing to lycopene